For patients with metastatic non-small cell lung cancer (NSCLC), the recent availability of immunotherapies, including immune checkpoint inhibitors (ICI) of programmed death 1 (PD-1) and PD-ligand 1 (PD-L1), has expanded the options for therapy (4, 5). This evidence concerns the gene CD274 and non-small cell lung carcinoma.